Share
Jerry Williamson
Phosphorex, a drug delivery-focused contract development and manufacturing organization (CDMO) and portfolio company of Ampersand Capital Partners, has appointed Jerry Williamson as Chief Executive Officer (CEO).
Mr. Williamson brings more than 35 years of leadership experience across bioscience, diagnostics, and life sciences, with a strong record of building innovative companies and delivering operational and commercial success. His appointment comes at a critical time as Phosphorex expands its expertise in lipid nanoparticle (LNP) formulation, process development, and cGMP manufacturing to support the growing demand for next-generation RNA, gene, and small molecule therapeutics.
Most recently, Mr. Williamson served as CEO of Sengenics, where he led the company’s transformation into a leader in immunology profiling. His earlier leadership roles include CEO positions at NanoView Biosciences, KEW, Inc., and Metamark Genetics. He also held senior executive roles as President of Genetix LLC, Biacore Inc., and Pyrosequencing, Inc.
Throughout his career, he has consistently guided companies through strategic growth, technology innovation, and market expansion, positioning them as leaders in their respective sectors.
Mr. Williamson’s extensive expertise will be instrumental in guiding Phosphorex through its next phase of innovation and growth.
